Dr. Reddy’s: FY27 EBITDA Margin Target at 20%

Key Update: New product launches and a strengthened base business are expected to support growth. The company has a long-term EBITDA margin target of 25%. For FY27, management expects EBITDA margin at around 20%. Growth is expected to be supported by product launches and improvement in the core business. Fundamental Ratios: Key metrics such as P/E, ROE, ROCE and debt-to-equity should be reviewed along with the latest financial results. Risk Factors: USFDA and other regulatory risks Pricing pressure in the US generics market Competition and product-launch delays Currency fluctuations R&D and manufacturing costs Disclaimer: This content is for educational and informational purposes only and should not be considered investment advice. Investors should conduct their own research and consult a SEBI-registered investment professional before making investment decisions.